Navigation Links
OncoGenex Reports Third Quarter Financial Results
Date:11/4/2010

ex applied for and is receiving these funds to support the company's custirsen and OGX-427 development projects.

Custirsen

  • With our partner Teva, we announced initiation of our second Phase 3 trial evaluating custirsen as first line therapy for the treatment of castrate-resistant prostate cancer (CRPC). The trial, which we are referring to as "The SYNERGY Trial," will be conducted in approximately 125 cancer centers and will enroll approximately 800 men who have disease progression and require first-line chemotherapy. The primary endpoint of the trial is overall survival.
  • The SYNERGY trial, along with "The Prostate Cancer Saturn Trial," which was initiated in June, comprises the Phase 3 development program to develop and commercialize custirsen in CRPC.  The Phase III trial in NSCLC is scheduled to commence in 2011.
  • Results from a randomized Phase 2 trial of docetaxel and prednisone with or without custirsen in patients with metastatic CRPC was published in the September 20, 2010 issue of the Journal of Clinical Oncology. The trial results showed a survival benefit with custirsen in patients with advanced prostate cancer. The median overall survival for patients who were treated with custirsen plus first-line docetaxel/prednisone was 23.8 months compared to 16.9 months for patients treated with docetaxel/prednisone alone.
  • OGX-427

  •  A randomized Phase 2 trial in CRPC was initiated in the third quarter of 2010. The Phase 2 trial will enroll up to 72 patients who have minimally symptomatic or asymptomatic advanced prostate cancer and who have not yet received chemotherapy. This trial is designed to determine the potential benefit of OGX-427 on disease progression, and will also measure the effect of OGX-427 on prostate specific antigen (PSA), time to progression, circulating tumor cells and other relevant secondary endpoints. Grant funding in support of this trial has been awarded by an independ
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related biology technology :

    1. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
    2. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
    3. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
    4. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
    5. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
    6. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
    7. OncoGenex Reports Second Quarter Financial Results
    8. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
    9. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
    10. OncoGenex Reports First Quarter Financial Results
    11. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2014)... 30, 2014   Wyle has been ... Lifecycle Mission Support Services (FILMSS) contract awarded by ... the terms of the contract, Wyle will provide ... Field, Calif. In particular, Wyle will provide program ... projects on the International Space Station and collaborative ...
    (Date:7/30/2014)... 30, 2014 BCC Research ( http://www.bccresearch.com ... for Enzymes in Industrial Applications , the global market ... $7.1 billion by 2018, registering a five-year compound annual ... to be recorded in the detergent enzyme segment with ... Enzyme technology has influenced almost every sector of industrial ...
    (Date:7/30/2014)... , July 30, 2014  Orexigen Therapeutics, Inc. ... received the Day 180 List of Outstanding Issues (LOI) ... for Human Use (CHMP) for the NB32 Marketing Authorization ... SR) is an investigational drug candidate being evaluated for ... earlier Day 120 time point were adequately addressed by ...
    (Date:7/30/2014)... 2014   Epic Sciences, Inc. ("Epic"), a ... to personalize and advance the treatment and management of ... Lucier as chairman of Epic,s board of directors. ... Technologies (formerly Invitrogen). Mr. Lucier joins Epic,s board of ... rare cell analysis platform with special focus on the ...
    Breaking Biology Technology:Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3
    ... Zyvex Labs today announced,its first company spinout: NanoMed, ... PhD, former Vice President of Research & Development ... Leader of Life Sciences,at Zyvex Corporation. NanoMed ... Life,Sciences. The company seeks to apply nanoparticle technologies ...
    ... ChemAxon, a software,solutions provider for cheminformatics, today ... application for working with chemical and,other data on ... brings,forms and form building, relational data support, advanced ... features the vast,majority of functionality and is free ...
    ... ,Courage Under Fire, WORCESTER, Mass., Aug. 21 ... is proud to announced that Dr.,Robert Lanza, the ... been recognized for his research and contributions to ... of PharmaVOICE (cover,story July/August issue). Dr. Lanza is ...
    Cached Biology Technology:NanoMed, Inc. Spins Out of Zyvex Labs 2Instant JChem 2.0 Released: Instant JChem Personal Free for All Users 2Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry' 2Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry' 3
    (Date:7/31/2014)... meta-analyses involving tree nuts (almonds, Brazil nuts, cashews, hazelnuts, ... published in the online publications, British Medical Journal ... (ii). The BMJ Open article looked ... (MetS) criteria and showed that tree nut consumption resulted ... glucose. The PLOS ONE article focused on ...
    (Date:7/30/2014)... Queen in Lewis Carroll,s Through the Looking Glass, ... University of Singapore improved a 35-year-old ecology model ... to millions of years. , The new model, ... the "Red Queen Effect," an evolutionary hypothesis introduced ... suggests that organisms must constantly increase their fitness ...
    (Date:7/30/2014)... of climate change on the world,s animal and ... according to a new paper by a research ... Queensland, and other organizations. The authors claim that ... point when it comes to climate change. ... focus on the "direct" threats of changing temperatures ...
    Breaking Biology News(10 mins):New international tree nut council study looks at nuts, diabetes and metabolic syndrome 2Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3Conservation scientists asking wrong questions on climate change impacts on wildlife 2
    ... and Drug Administration approved a drug called BiDil as ... claiming in a press release that this was a ... Science, Politics and Big Business Re-create Race in the ... Kirkland & Ellis Professor at Northwestern University School of ...
    ... responses are some of the most studied behaviors by ... sensory information. The ability to evade predators plays a ... explore their environment to find food, find mates and ... to avoid predators, thereby increasing their chances for survival. ...
    ... over Niagara Falls. Pollution from fires in Ontario, Canada ... being measured by NASA,s Aqua satellite. One instrument ... two views of the pollution from the fires in ... flies onboard NASA,s Aqua and Terra satellites. MODIS has ...
    Cached Biology News:Divided by race 2Elusive prey 2NASA measures wildfire pollution pour over Niagara Falls 2
    ...
    DryStrip aligners, 4. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
    Immunogen: Peptide corresponding to amino acid residues from the N-terminal region of human thyroid hormone receptor, alpha1/alpha2-isotype. Storage: -20 C, Avoid Freeze/Thaw Cycles...
    ...
    Biology Products: